Diarrhea News and Research RSS Feed - Diarrhea News and Research

Diarrhea is loose, watery stools. A person with diarrhea typically passes stool more than three times a day. People with diarrhea may pass more than a quart of stool a day. Acute diarrhea is a common problem that usually lasts 1 or 2 days and goes away on its own without special treatment. Prolonged diarrhea persisting for more than 2 days may be a sign of a more serious problem and poses the risk of dehydration. Chronic diarrhea may be a feature of a chronic disease.

Diarrhea can cause dehydration, which means the body lacks enough fluid to function properly. Dehydration is particularly dangerous in children and older people, and it must be treated promptly to avoid serious health problems.
Vinegar could help fight ulcerative colitis

Vinegar could help fight ulcerative colitis

Vinegar is the perfect ingredient for making tangy sauces and dressings. Now, researchers report in ACS' Journal of Agricultural and Food Chemistry that the popular liquid could also help fight ulcerative colitis, an inflammatory bowel disease that research suggests is related to the gut microbiome. [More]
Oral therapeutic drug shows promise against recurrent C. difficile infection

Oral therapeutic drug shows promise against recurrent C. difficile infection

Results from a Phase 1b/2 trial suggest that an investigational microbiome-based, oral therapeutic drug is effective for the treatment of recurrent C. difficile infection. In a paper published online in the Journal of Infectious Diseases, a multi-institutional research team reports that treatment with the preparation, containing the spores of approximately 50 species of beneficial bacteria, successfully prevented recurrence of C. difficile infection (CDI) in patients with a history of multiple recurrent disease. [More]
UM SOM researchers reveal genetic makeup of various strains of E. coli

UM SOM researchers reveal genetic makeup of various strains of E. coli

A multi-disciplinary group of researchers at the University of Maryland School of Medicine have for the first time determined the genetic makeup of various strains of E. coli, which every year kills hundreds of thousands of people around the world. [More]
Discovery takes researchers one step closer to preventing C. diff

Discovery takes researchers one step closer to preventing C. diff

Exposure to specific antibiotics is linked to the development of certain strains of antibiotic-resistant C. difficile, one of the fastest growing bacteria superbugs, according to a new study published by Stuart Johnson, MD, of Loyola University Health System, Loyola University Chicago Stritch School of Medicine and the Hines VA Medical Hospital. [More]

OASIS clinical study evaluates investigational medication for treatment of UC

Ulcerative Colitis (UC) is a chronic disease of the colon that causes the colon to become inflamed and forms ulcers. UC is a type of irritable bowel disease (IBD), which is a term that describes conditions with chronic or recurring inflammation of the gastrointestinal tract. [More]
TPC reports first cases of illness, deaths due to Dewshine mixture in Tennessee

TPC reports first cases of illness, deaths due to Dewshine mixture in Tennessee

A lethal concoction of racing fuel and Mountain Dew claimed the lives of two Tennessee teens and has sparked the Tennessee Poison Center to warn about the lethality of what has been called "Dewshine." [More]
UI researchers remind US doctors to watch for two diseases that could be passed from mother to child

UI researchers remind US doctors to watch for two diseases that could be passed from mother to child

While world health leaders race to contain the spread of the mosquito-borne Zika virus in the Americas, researchers at the University of Iowa are reminding doctors in the United States to be on the lookout for two other vector-borne and potentially life-threatening diseases that can be passed from mother to child through the placenta. [More]
Costs of lower cognitive ability linked with not breastfeeding amount to over $300 billion each year

Costs of lower cognitive ability linked with not breastfeeding amount to over $300 billion each year

When countries, rich or poor, support breastfeeding through meaningful investments and programs, it has an impact on their bottom line and the health of women and children. The Lancet Breastfeeding Series, released today, finds that globally, the costs of lower cognitive ability associated with not breastfeeding amount to more than $300 billion each year, a figure comparable to the entire global pharmaceutical market. [More]
FDA expands use of Opdivo + Yervoy Regimen for BRAF V600 mutant and wild-type advanced melanoma

FDA expands use of Opdivo + Yervoy Regimen for BRAF V600 mutant and wild-type advanced melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved Opdivo in combination with Yervoy for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma. [More]
New case of MERS CoV confirmed in Thailand, other states in WHO South-East Asia Region cautioned to remain vigilant

New case of MERS CoV confirmed in Thailand, other states in WHO South-East Asia Region cautioned to remain vigilant

Thailand today confirmed Middle East respiratory syndrome coronavirus disease in a traveler, the second such case in the country in the last seven months, as WHO cautioned other member states in its South-East Asia Region against the continuing risks and the need to remain vigilant. [More]
Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Astellas US LLC, a United States (U.S.) subsidiary of Tokyo-based Astellas Pharma Inc., and Medivation, Inc. today announced that results from the STRIVE trial of enzalutamide compared to bicalutamide in men with castration-resistant prostate cancer (CRPC) were published in the Journal of Clinical Oncology. [More]
Building Health Check launches IAQ Screening Kit for E. coli bacteria

Building Health Check launches IAQ Screening Kit for E. coli bacteria

Following a number of recent outbreaks of E. coli, or Escherichia coli, bacteria at grocers and restaurants across the country, Building Health Check, LLC, has released an Indoor Air Quality (IAQ) Screening Kit for the E. coli bacteria. [More]
FDA approves Allergan's sNDA to update label for DALVANCE (dalbavancin) for injection

FDA approves Allergan's sNDA to update label for DALVANCE (dalbavancin) for injection

Allergan plc, a leading global pharmaceutical company, today announced the U.S. Food and Drug Administration has approved the company's supplemental new drug application (sNDA) to update the label for DALVANCE (dalbavancin) for injection. [More]
Allergan announces publication of VIBERZI Phase III trial results in The New England Journal of Medicine

Allergan announces publication of VIBERZI Phase III trial results in The New England Journal of Medicine

Allergan plc announced today the publication of the positive results of the Phase III trials of VIBERZITM C IV (eluxadoline) for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in the January 21 issue of The New England Journal of Medicine. [More]
Mayo Clinic adds robots to prevent C-diff bacteria

Mayo Clinic adds robots to prevent C-diff bacteria

Mayo Clinic has added robots in its fight against Clostridium difficile (C-diff) bacteria. In the U.S., C-diff is one of the most common infections patients can get while receiving care at a health care facility. C-diff can cause a variety of symptoms, including potentially deadly diarrhea. A recent national report shows some progress in reducing C-diff infections; however, more work remains. [More]
Frozen fecal transplantation effective at providing relief to C. diff patients

Frozen fecal transplantation effective at providing relief to C. diff patients

Frozen fecal transplantation is effective at providing relief to Clostridium difficile (C. diff) patients, according to a new study co-authored by University of Guelph researchers. [More]
Anti-cancer drug uses 50 times less chemo to effectively destroy drug-resistant lung cancer

Anti-cancer drug uses 50 times less chemo to effectively destroy drug-resistant lung cancer

The cancer drug paclitaxel just got more effective. For the first time, researchers from the University of North Carolina at Chapel Hill have packaged it in containers derived from a patient's own immune system, protecting the drug from being destroyed by the body's own defenses and bringing the entire payload to the tumor. [More]
Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announced today that the US Food and Drug Administration has approved Cosentyx (secukinumab) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). [More]
Simple paper test could confirm presence of illnesses even before patients feel symptoms

Simple paper test could confirm presence of illnesses even before patients feel symptoms

A multi-disciplinary team of researchers has developed a new diagnostic test that can change the medical landscape by making it possible for patients to quickly determine if they are infected with an illness, using a simple paper test sensitive enough to detect markers of various illnesses using minute amounts of blood, sweat, or other biological material. [More]
Researcher seeks to identify probiotic mixes to treat Clostridium difficile infections

Researcher seeks to identify probiotic mixes to treat Clostridium difficile infections

Antibiotics that fight infection can adversely affect the digestive tract and give destructive bacteria a chance to flourish, said assistant professor of veterinary and biomedical sciences Joy Scaria of South Dakota State University. His research seeks to identify probiotic mixes to treat intestinal infections, such as Clostridium difficile. [More]
Advertisement